



MagArray
REVEAL
 LUNG NODULE CHARACTERIZATION

FINAL REPORT

Collected: XX/XX/XXXX

Received: XX/XX/XXXX


Report Date: XX/XX/XXXX

Referring Physician: XXXXXXXXXXXXXXXXXXXX
 Physician NPI#: XXXXXXXXXXXXXXXXXXXX
 Address: XXXXXXXXXXXXXXXXXXXX
 City / State / ZIP: XXXXXXXXXXXXXXXXXXXX
 Country: XXXXXXXXXXXXXXXXXXXX

Specimen Number: XXXXXXXXX
 Patient Name: XXXXXXXXXXXXXXX
 DOB: XX/XX/XXXX

REVEAL Lung Nodule Characterization Test Results

RISK OF NODULE MALIGNANCY



Reportable Range	Patient REVEAL Result		
0 - 100	Specimen Number	Score	Risk Category
	XXXXXXXX	25	Lower

Lower Risk

Relatively lower risk of lung cancer. **Consistent with REVEAL scores in a clinical study where 94% of the subjects with a score of 49 or less had benign disease (1).** REVEAL is a risk assessment tool, which is to be used only in conjunction with standard clinical assessments. **The test is not intended as a screening or stand-alone diagnostic assay.**

1. Trivedi et al, Biomedical Research and Clinical Practice, 2018. 2. Trivedi et al, Biomedical Research and Reviews, 2018.

The REVEAL Lung Nodule Characterization test is based on a multianalyte assay with an algorithmic analysis that is proprietary to MagArray, Inc. The test uses immunoassay, microarray, and magnetic nanoparticle detection techniques to obtain laboratory data for analysis and calculation of the resulting risk score of lung cancer. Please visit www.magarray.com for more information.

The performance characteristics of this test were validated by MagArray, Inc. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. **The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.** MagArray, Inc. is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. Test performed at MagArray, Inc.